Preventive cardiologyMeta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus
Section snippets
Methods
Established methods were used in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement for reporting systematic reviews and meta-analyses in health care interventions.5 A search of pertinent RCTs conducted from November 1994 to October 2012 was performed by 2 independent investigators covering the MEDLINE, Cochrane, Google Scholar, and Embase databases as well as abstracts and presentations from major cardiovascular meetings, using the search string
Results
The flow diagram of the study is shown in Figure 1. Seventeen RCTs8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 fulfilling the eligibility criteria and comprising a total of 113,394 patients were eventually included for data abstraction. Table 1 lists the main characteristics of the included studies. Fourteen RCTs compared a statin with placebo, and 3 studies compared high- with moderate-dose statin therapy. The high daily doses of statins used in the RCTs were atorvastatin
Discussion
The present study is the largest and most comprehensive study thus far comparing rates of new-onset DM among different types and doses of statins. The main findings derived from a population of 113,394 patients were as follows: (1) there was a gradient for the risk for new-onset DM across different types and doses of statins, (2) pravastatin therapy was numerically associated with the lowest rate of new-onset DM compared with other statins, whereas treatment with rosuvastatin was associated
Acknowledgment
The present study is a project of Systematic Investigation and Research on Interventions and Outcomes (SIRIO)–MEDICINE, an international scientific group committed to research and innovation in medicine.
References (29)
- et al.
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation
Am J Cardiol
(2011) - et al.
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Lancet
(2010) - et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Lancet
(2003) - et al.
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Lancet
(2002) - et al.
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
Lancet
(2006) - et al.
Caveats to aggressive lowering of lipids by specific statins
Int J Cardiol
(2012) - et al.
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis
JAMA
(2011) - United States Food and Drug Administration. FDA expands advice on statin risks. Available at:...
- et al.
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
BMJ
(2009) - et al.
Combination of direct and indirect evidence in mixed treatment comparisons
Stat Med
(2004)
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
Lancet
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
N Engl J Med
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
Circulation
Cited by (0)
See page 1129 for disclosure information.